As reported on November 19, 2026, a shortage of Sanofi’s Pompe disease treatments had lasted more than three months, causing some patients to miss scheduled infusions. Sanofi said manufacturing issues at its facility in Ireland were behind the disruption. The company said it had made progress restoring supply in some countries, but shipping delays could interrupt infusions for some U.S. patients through the end of November.
Pompe disease weakens muscles, and patients typically receive Sanofi’s enzyme-replacement treatments, Lumizyme or Nexviazyme, every two weeks. Monique Griffin, 51, said her next Lumizyme infusion had been canceled after Sanofi notified her of a shipping delay. She fears that a prolonged interruption could worsen her condition.
The FDA inspected Sanofi’s Irish facility in January 2026 and identified manufacturing violations involving two drugs unrelated to the Pompe treatments. In a June 22 warning letter, the agency said Sanofi had not addressed an underlying failure to comply with manufacturing requirements. Sanofi said work to address the FDA’s continuing concerns contributed to the Pompe treatment supply disruption; its spokesman said there were no drug-quality issues.
Some patients and families criticized the company’s communication about the shortage. Sanofi said it had informed patient groups, patients and clinicians as the extent of the disruption became clearer and was continuing to provide updates. The FDA said patient access was a priority and that it had offered Sanofi assistance. Sanofi said it was prioritizing the most vulnerable patients and advised patients to consult a health professional before changing treatments, noting that the medicines are not interchangeable.
